Oral isotretinoin for treating mucocutaneous human papillomavirus infections: A systematic review and meta-analysis
Indian J Dermatol Venereol Leprol
;
2019 Nov; 85(6): 569-577
Article
| IMSEAR
| ID: sea-192524
ABSTRACT
Introduction:
Some viral warts are refractory to treatment, some others tend to recur. Oral isotretinoin is useful against warts to varying degrees.Objective:
To determine the efficacy of oral isotretinoin for treating mucocutaneous human papillomavirus infections.Methods:
A systematic review and meta-analysis of studies published from the date of inception of the databases to December 30, 2017 were conducted. Randomized controlled trials or case series with ≥10 patients with mucocutaneous human papillomavirus infection who had received oral isotretinoin treatment were analyzed. The meta-analysis estimated the pooled odds ratio and pooled response rate.Results:
The review included eight studies. Trials of oral isotretinoin versus placebo treatment revealed that isotretinoin effectively treated mucocutaneous human papillomavirus infections (odds ratio 43.8, 95% confidence interval 9.7–198.8). The pooled estimate of the complete response rate of oral isotretinoin to mucocutaneous human papillomavirus was 67.7% (95% confidence interval 49.5–81.7%). Another pooled estimation revealed that 83.9% (95% confidence interval 59.7–94.9%) of patients exhibited at least 50% lesion clearance, whereas 12.3% with complete response experienced recurrence.Limitations:
This meta-analysis had a small sample size and high inter-study heterogeneity.Conclusion:
Oral isotretinoin is superior to placebo for treating mucocutaneous human papillomavirus infections, particularly plane warts. The recurrence rate and risk of severe side effects are low.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Type of study:
Controlled clinical trial
/
Systematic reviews
Journal:
Indian J Dermatol Venereol Leprol
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS